Pfizer said on Tuesday that it has reached settlement agreements with three generic manufacturers — Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd. — resolving patent-infringement lawsuits over ...
BridgeBio Pharma, Inc. remains a Buy, driven by Attruby’s strong U.S. launch and favorable competitive dynamics. Learn more ...
BridgeBio Pharma recently reported a strong and accelerating launch of its heart drug Attruby, with rapid growth in unique patient prescriptions and prescribers, supported by compelling clinical ...
BridgeBio (BBIO) rose 6.6% after a court filing disclosed a settlement in a generic patent case over Pfizer's (PFE) Vyndamax ...
Investors may be wondering if BridgeBio Pharma (NASDAQ: BBIO) still offers value after a strong run, or if most of the upside is already priced in. The stock last closed at US$73.28, with returns of ...
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in BridgeBio Pharma Inc (Symbol: BBIO), where a total of 16,287 contracts have traded so far, ...
Investors in BridgeBio Pharma Inc (Symbol: BBIO) saw new options become available this week, for the May 2026 expiration. One of the key data points that goes into the price an option buyer is willing ...
We recently published an article titled 10 Firms Post Impressive Gains on Tuesday. In this article, we are going to take a look at where BridgeBio Pharma, Inc. (NASDAQ:BBIO) stands against the other ...
BridgeBio rose 2.9% after a court filing appeared to indicate a settlement in a generic patent case over Pfizer's Vyndamax ...
BridgeBio Pharma Inc (NASDAQ:BBIO) announced the presentation of detailed results from its Phase 3 ATTRibute-CM study of acoramidis for ATTR-CM at the European Society of Cardiology Congress 2023.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results